Fig. 5From: Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective studyOverall survival (OS), progression-free survival (PFS) and intrahepatic PFS (IHPFS) in the subgroups. A The OS in the Vp1-2 subgroup. B The PFS in the Vp1-2 subgroup. C The IHPFS in Vp1-2 subgroup. D The OS in the Vp3-4 subgroup. E The PFS in the Vp3-4 subgroup. F The IHPFS in Vp3-4 subgroupBack to article page